Leukemia - Leuchaemia | Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors
Creators: name: Tsanov, Vasil
Publisher: name: figshare
Year: 2023
Subjects: classificationCode: 310102
subject: Cell development, proliferation and death
classificationCode: 310103
subject: Cell metabolism
classificationCode: 310199
subject: Biochemistry and cell biology not elsewhere classified
classificationCode: 310204
subject: Genomics and transcriptomics
classificationCode: 310299
subject: Bioinformatics and computational biology not elsewhere classified
classificationCode: 310208
subject: Translational and applied bioinformatics
classificationCode: 310202
subject: Biological network analysis
classificationCode: 310510
subject: Molecular evolution
classificationCode: 319999
subject: Other biological sciences not elsewhere classified
classificationCode: 320502
subject: Medical biochemistry - carbohydrates
classificationCode: 320599
subject: Medical biochemistry and metabolomics not elsewhere classified
classificationCode: 321101
subject: Cancer cell biology
classificationCode: 321104
subject: Cancer therapy (excl. chemotherapy and radiation therapy)
classificationCode: 321199
subject: Oncology and carcinogenesis not elsewhere classified
classificationCode: 321106
subject: Haematological tumours
classificationCode: 321111
subject: Solid tumours
classificationCode: 321399
subject: Paediatrics not elsewhere classified
classificationCode: 329999
subject: Other biomedical and clinical sciences not elsewhere classified
classificationCode: 340502
subject: Natural products and bioactive compounds
classificationCode: 340599
subject: Organic chemistry not elsewhere classified
classificationCode: 340401
subject: Biologically active molecules
classificationCode: 340404
subject: Cheminformatics and quantitative structure-activity relationships
classificationCode: 340406
subject: Molecular medicine
classificationCode: 340499
subject: Medicinal and biomolecular chemistry not elsewhere classified
classificationCode: 349999
subject: Other chemical sciences not elsewhere classified

description: A T L A S - Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors - DOI: 10.5281/zenodo.8009390 | ISBN: 978-619-91534-5-1-------From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (<i><b>p.10</b></i><i> form the ATLAS</i>) of transcriptome cell lines inherent in tumors in the Leukemia (<i><b>a. </b></i>&amp;<i><b> b.</b></i>), it is concluded that:- main potential medicines: <i><b>AACF 1.C.</b></i>,<i><b> 4.C.</b></i>,<i><b> 5.C.</b></i>,<i><b> 5.D.</b></i>,<i><b> 19</b></i><i><b>.</b></i>,<i><b> 25</b></i><i><b>.</b></i>,<i><b> 30</b></i><i><b>.</b></i>,<i><b> 31.B.</b></i>,<i><b> 31.C.</b></i>,<i><b> 34</b></i><i><b>.</b></i>,<i><b> 39</b></i><i><b>.</b></i>,<i><b> 40</b></i><i><b>.</b></i>,<i><b> 45.E</b></i><i><b>.</b></i>,<i><b> 50</b></i><i><b>.</b></i>,<i><b> 56.A. </b></i>and<i><b> 56.B.</b></i>;- duplication of treatment and / or substitution on medical grounds: <i><b>AACF 1.D.</b></i>,<i><b> 4.A.</b></i>,<i><b> 4.B.</b></i>,<i><b> 5.A.</b></i>,<i><b> 5.B.</b></i>,<i><b> 7</b></i><i><b>.</b></i>,<i><b> 12</b></i><i><b>.</b></i>,<i><b> 32</b></i><i><b>.</b></i>,<i><b> 33</b></i><i><b>.</b></i>,<i><b> 42</b></i><i><b>.</b></i>,<i><b> 43</b></i><i><b>.</b></i>,<i><b> 44</b></i><i><b>.</b></i>,<i><b> 45.B.</b></i>,<i><b> 49</b></i><i><b>.</b></i>,<i><b> 50</b></i><i><b>.</b></i>,<i><b> 51.A. </b></i>and<i><b> 51.B</b></i>.-------Active pharmaceutical forms for oral use and their corresponding active anti-cancer molecules obtained after passage through the cell membrane, based on hydrolyzed amide/carboxylic acid derivatives of natural nitrile glycosides - <i><b>p.10</b></i>Important! Do not forget to comply with the current clinical control - <i><b>p.148</b></i>Intake methodology and working concentrations - <i><b>p.154</b></i>